Anti-IL-1-/-3 p40 antibody attenuates experimental chronic graft-versus-host disease via suppression of IFN-γ/IL-17-producing cells

Journal of Immunology

Volumn 194, Issue 3, 2015, Pages 1357-1363

  Okamoto, Sachiyo ^a   Fujiwara, Hideaki ^a   Nishimori, Hisakazu ^a   Matsuoka, Ken Ichi ^a   Fujii, Nobuharu ^a   Kondo, Eisei ^a   Tanaka, Takehiro ^a   Yoshimura, Akihiko ^b   Tanimoto, Mitsune ^a   Maeda, Yoshinobu ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 12 ANTIBODY; INTERLEUKIN 17; INTERLEUKIN 22; INTERLEUKIN 23 ANTIBODY; MONOCLONAL ANTIBODY; P40 MONOCLONAL ANTIBODY; PROTEIN ANTIBODY; PROTEIN P40; PROTEIN P40 ANTIBODY; TRANSCRIPTION FACTOR T BET; UNCLASSIFIED DRUG; INTERLEUKIN 12P40;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; CD4+ T LYMPHOCYTE; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; FEMALE; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; ADVERSE EFFECTS; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; BONE MARROW TRANSPLANTATION; CHRONIC DISEASE; DISEASE MODEL; DRUG EFFECTS; GRAFT VS HOST DISEASE; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; METABOLISM; T LYMPHOCYTE SUBPOPULATION; TH17 CELL;

ANIMALS; ANTIBODIES, MONOCLONAL; BONE MARROW TRANSPLANTATION; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; FEMALE; GRAFT VS HOST DISEASE; INTERFERON-GAMMA; INTERLEUKIN-12 SUBUNIT P40; INTERLEUKIN-17; MICE; T-LYMPHOCYTE SUBSETS; TH17 CELLS; TRANSPLANTATION CONDITIONING;

EID: 84921483083     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1400973     Document Type: Article

References (39)

1. Teshima, T., T. A. Wynn, R. J. Soiffer, K. Matsuoka, and P. J. Martin. 2008. Chronic graft-versus-host disease: how can we release Prometheus? Biol. Blood Marrow Transplant. 14: 142-150.
2. Socie, G., J. V. Stone, J. R. Wingard, D. Weisdorf, P. J. Henslee-Downey, C. Bredeson, J. Y. Cahn, J. R. Passweg, P. A. Rowlings, H. C. Schouten, et al. 1999. Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry. N. Engl. J. Med. 341: 14-21.
3. Baker, K. S., J. G. Gurney, K. K. Ness, R. Bhatia, S. J. Forman, L. Francisco, P. B. McGlave, L. L. Robison, D. S. Snyder, D. J. Weisdorf, and S. Bhatia. 2004. Late effects in survivors of chronic myeloid leukemia treated with hematopoietic cell transplantation: results from the Bone Marrow Transplant Survivor Study. Blood 104: 1898-1906.
4. Wolff, D., M. Schleuning, S. von Harsdorf, U. Bacher, A. Gerbitz, M. Stadler, F. Ayuk, A. Kiani, R. Schwerdtfeger, G. B. Vogelsang, et al. 2011. Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-versus-Host Disease. Biol. Blood Marrow Transplant. 17: 1-17.
5. Akpek, G., M. L. Zahurak, S. Piantadosi, J. Margolis, J. Doherty, R. Davidson, and G. B. Vogelsang. 2001. Development of a prognostic model for grading chronic graft-versus-host disease. Blood 97: 1219-1226.
6. Loh, J., B. Knoechel, J. J. Wang, A. V. Villarino, and A. K. Abbas. 2006. Role of IL-17 and regulatory T lymphocytes in a systemic autoimmune disease. J. Exp. Med. 203: 2785-2791.
7. Zhou, L., D. Askew, C. Wu, and A. C. Gilliam. 2007. Cutaneous gene expression by DNA microarray in murine sclerodermatous graft-versus-host disease, a model for human scleroderma. J. Invest. Dermatol. 127: 281-292.
8. Chen, X., S. Vodanovic-Jankovic, B. Johnson, M. Keller, R. Komorowski, and W. R. Drobyski. 2007. Absence of regulatory T-cell control of TH1 and TH17 cells is responsible for the autoimmune-mediated pathology in chronic graftversus-host disease. Blood 110: 3804-3813.
9. Hill, G. R., S. D. Olver, R. D. Kuns, A. Varelias, N. C. Raffelt, A. L. Don, K. A. Markey, Y. A. Wilson, M. J. Smyth, Y. Iwakura, et al. 2010. Stem cell mobilization with G-CSF induces type 17 differentiation and promotes scleroderma. Blood 116: 819-828.
10. Nishimori, H., Y. Maeda, T. Teshima, H. Sugiyama, K. Kobayashi, Y. Yamasuji, S. Kadohisa, H. Uryu, K. Takeuchi, T. Tanaka, et al. 2012. Synthetic retinoid Am80 ameliorates chronic graft-versus-host disease by down-regulating Th1 and Th17. Blood 119: 285-295.
11. Dander, E., A. Balduzzi, G. Zappa, G. Lucchini, P. Perseghin, V. Andrè, E. Todisco, D. Rahal, M. Migliavacca, D. Longoni, et al. 2009. Interleukin-17-producing T-helper cells as new potential player mediating graft-versus-host disease in patients undergoing allogeneic stem-cell transplantation. Transplantation 88: 1261-1272.
12. Ritchie, D., J. Seconi, C. Wood, J. Walton, and V. Watt. 2005. Prospective monitoring of tumor necrosis factor alpha and interferon gamma to predict the onset of acute and chronic graft-versus-host disease after allogeneic stem cell transplantation. Biol. Blood Marrow Transplant. 11: 706-712.
13. Körholz, D., D. Kunst, L. Hempel, D. Söhngen, A. Heyll, H. Bönig, U. Göbel, F. Zintl, and S. Burdach. 1997. Decreased interleukin 10 and increased interferon-gamma production in patients with chronic graft-versus-host disease after allogeneic bone marrow transplantation. Bone Marrow Transplant. 19: 691-695.
14. Ochs, L. A., B. R. Blazar, J. Roy, E. B. Rest, and D. J. Weisdorf. 1996. Cytokine expression in human cutaneous chronic graft-versus-host disease. Bone Marrow Transplant. 17: 1085-1092.
15. Imanguli, M. M., W. D. Swaim, S. C. League, R. E. Gress, S. Z. Pavletic, and F. T. Hakim. 2009. Increased T-bet+ cytotoxic effectors and type I interferonmediated processes in chronic graft-versus-host disease of the oral mucosa. Blood 113: 3620-3630.
16. Boniface, K., W. M. Blumenschein, K. Brovont-Porth, M. J. McGeachy, B. Basham, B. Desai, R. Pierce, T. K. McClanahan, S. Sadekova, and R. de Waal Malefyt. 2010. Human Th17 cells comprise heterogeneous subsets including IFN-gamma-producing cells with distinct properties from the Th1 lineage. J. Immunol. 185: 679-687.
17. Suryani, S., and I. Sutton. 2007. An interferon-gamma-producing Th1 subset is the major source of IL-17 in experimental autoimmune encephalitis. J. Neuroimmunol. 183: 96-103.
18. Acosta-Rodriguez, E. V., L. Rivino, J. Geginat, D. Jarrossay, M. Gattorno, A. Lanzavecchia, F. Sallusto, and G. Napolitani. 2007. Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat. Immunol. 8: 639-646.
19. Annunziat, F., L. Cosmi, V. Santarlasci, L. Maggi, F. Liotta, B. Mazzinghi, E. Parente, L. Filì, S. Ferri, F. Frosali, et al. 2007. Phenotypic and functional features of human Th17 cells. J. Exp. Med. 204: 1849-1861.
20. Cosmi, L., R. De Palma, V. Santarlasci, L. Maggi, M. Capone, F. Frosali, G. Rodolico, V. Querci, G. Abbate, R. Angeli, et al. 2008. Human interleukin 17-producing cells originate from a CD161+CD4+ T cell precursor. J. Exp. Med. 205: 1903-1916.
21. Luger, D., P. B. Silver, J. Tang, D. Cua, Z. Chen, Y. Iwakura, E. P. Bowman, N. M. Sgambellone, C. C. Chan, and R. R. Caspi. 2008. Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector category. J. Exp. Med. 205: 799-810.
22. McGeachy, M. J., K. S. Bak-Jensen, Y. Chen, C. M. Tato, W. Blumenschein, T. McClanahan, and D. J. Cua. 2007. TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology. Nat. Immunol. 8: 1390-1397.
23. Ahern, P. P., C. Schiering, S. Buonocore, M. J. McGeachy, D. J. Cua, K. J. Maloy, and F. Powrie. 2010. Interleukin-23 drives intestinal inflammation through direct activity on T cells. Immunity 33: 279-288.
24. Hirota, K., J. H. Duarte, M. Veldhoen, E. Hornsby, Y. Li, D. J. Cua, H. Ahlfors, C. Wilhelm, M. Tolaini, U. Menzel, et al. 2011. Fate mapping of IL-17-producing T cells in inflammatory responses. Nat. Immunol. 12: 255-263.
25. Peters, A., Y. Lee, and V. K. Kuchroo. 2011. The many faces of Th17 cells. Curr. Opin. Immunol. 23: 702-706.
26. Yen, D., J. Cheung, H. Scheerens, F. Poulet, T. McClanahan, B. McKenzie, M. A. Kleinschek, A. Owyang, J. Mattson, W. Blumenschein, et al. 2006. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J. Clin. Invest. 116: 1310-1316.
27. Ghoreschi, K., A. Laurence, X. P. Yang, C. M. Tato, M. J. McGeachy, J. E. Konkel, H. L. Ramos, L. Wei, T. S. Davidson, N. Bouladoux, et al. 2010. Generation of pathogenic T(H)17 cells in the absence of TGF-beta signalling. Nature 467: 967-971.
28. Volpe, E., N. Servant, R. Zollinger, S. I. Bogiatzi, P. Hupé, E. Barillot, and V. Soumelis. 2008. A critical function for transforming growth factor-beta, in-terleukin 23 and proinflammatory cytokines in driving and modulating human T (H)-17 responses. Nat. Immunol. 9: 650-657.
29. -/-3 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, doubleblind, placebo-controlled trial (PHOENIX 1). Lancet 371: 1665-1674.
30. -/-3 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 371: 1675-1684.
31. McInnes, I. B., A. Kavanaugh, A. B. Gottlieb, L. Puig, P. Rahman, C. Ritchlin, C. Brodmerkel, S. Li, Y. Wang, A. M. Mendelsohn, and M. K. Doyle, PSUMMIT 1 Study Group. 2013. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 382: 780-789.
32. Sandborn, W. J., C. Gasink, L. L. Gao, M. A. Blank, J. Johanns, C. Guzzo, B. E. Sands, S. B. Hanauer, S. Targan, P. Rutgeerts, et al; CERTIFI Study Group. 2012. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N. Engl. J. Med. 367: 1519-1528.
33. Sugiyama, H., Y. Maeda, H. Nishimori, Y. Yamasuji, K. Matsuoka, N. Fujii, E. Kondo, K. Shinagawa, T. Tanaka, K. Takeuchi, et al. 2014. Mammalian target of rapamycin inhibitors permit regulatory T cell reconstitution and inhibit experimental chronic graft-versus-host disease. Biol. Blood Marrow Transplant. 20: 183-191.
34. Zhao, D., J. S. Young, Y. H. Chen, E. Shen, T. Yi, I. Todorov, P. G. Chu, S. J. Forman, and D. Zeng. 2011. Alloimmune response results in expansion of autoreactive donor CD4+ T cells in transplants that can mediate chronic graftversus-host disease. J. Immunol. 186: 856-868.
35. Wang, Y., J. Godec, K. Ben-Aissa, K. Cui, K. Zhao, A. B. Pucsek, Y. K. Lee, C. T. Weaver, R. Yagi, and V. Lazarevic. 2014. The transcription factors T-bet and Runx are required for the ontogeny of pathogenic interferon-γ-producing T helper 17 cells. Immunity 40: 355-366.
36. Sabat, R., W. Ouyang, and K. Wolk. 2014. Therapeutic opportunities of the IL-22-IL-22R1system. Nat. Rev. Drug Discov. 13: 21-38.
37. Cua, D. J., J. Sherlock, Y. Chen, C. A. Murphy, B. Joyce, B. Seymour, L. Lucian, W. To, S. Kwan, T. Churakova, et al. 2003. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 421: 744-748.
38. Murphy, C. A., C. L. Langrish, Y. Chen, W. Blumenschein, T. McClanahan, R. A. Kastelein, J. D. Sedgwick, and D. J. Cua. 2003. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J. Exp. Med. 198: 1951-1957.
39. Becker, C., H. Dornhoff, C. Neufert, M. C. Fantini, S. Wirtz, S. Huebner, A. Nikolaev, H. A. Lehr, A. J. Murphy, D. M. Valenzuela, et al. 2006. Cutting edge: IL-23 cross-regulates IL-12 production in T cell-dependent experimental colitis. J. Immunol. 177: 2760-2764.